TRX-44 / Tribune Therapeutics - LARVOL DELTA

Novo Holdings participates in €23 million Series A for Tribune Therapeutics to advance next-generation anti-fibrotic therapies (PRNewswire) - "Novo Holdings today announced its participation in a €23 million Series A round for Tribune Therapeutics ('Tribune'). The round was led by new investor LifeArc Ventures and joined by Novo Holdings, HealthCap, Innovestor's Life Science Fund and Inven2 as well as new Series A investors Industrifonden and Investinor....Tribune's lead programme, TRX-44, is currently in development for the treatment of fibrotic conditions including idiopathic pulmonary fibrosis (IPF)."

Financing • Idiopathic Pulmonary Fibrosis